headshot photo of Dr. Khaled Elsaid

Dr. Khaled Elsaid

Associate Professor
School of Pharmacy
Expertise: Inflammation Pharmacology; Drug Discovery; Arthritis Models; Arthritic Diseases; Innate Immunity
Office Location: 297O
Phone: (714) 516-5435
Scholarly Works:
Digital Commons
Education:
Cairo University, Bachelor of Science
University of Rhode Island, Master of Science
University of Rhode Island, Master of Business Admin.
Massachusetts College of Pharmacy and Health Sciences, Doctor of Pharmacy
University of Rhode Island, Ph.D.

Biography

Dr. Khaled A. Elsaid joined CUSP on August 1, 2016 as a tenure-track associate professor of pharmacology and was awarded tenure in May 2019.  Dr. Elsaid graduated with a Bachelor of Science in Pharmaceutical Sciences from Cairo University in 1997.  He traveled to the U.S. for his graduate education at the University of Rhode Island (URI) in 1999.  Over a 6-year period (1999-2005), he earned an MS in Biomedical Sciences, a Ph.D. in Pharmacology and Toxicology, and a Master’s in Business Administration (MBA).  After graduation, Dr. Elsaid worked as a research associate in Rhode Island Hospital (RIH) and Brown University Medical School for four years.  While working as a research associate, he earned his post-B.S. doctor of pharmacy (Pharm.D.) degree from the Massachusetts College of Pharmacy and Health Sciences (MCPHS) and worked as a clinical pharmacist at RIH.  In summer 2009, Dr. Elsaid was appointed as an assistant professor of pharmacology and toxicology at MCPHS-Boston.  Dr. Elsaid developed, coordinated, and taught pharmacology courses in the undergraduate, Pharm.D., and graduate programs.  Dr. Elsaid developed an NIH-funded research program at MCPHS and was promoted to associate professor in summer 2014.  Dr. Elsaid mentored several graduate students in the M.S. and Ph.D. programs in pharmacology.  At Chapman University, Dr. Elsaid continued his work related to the understanding of the pathogenesis of chronic degenerative joint diseases, e.g., osteoarthritis and crystal-induced arthropathies, e.g., gout and pseudogout.  At Chapman, Dr. Elsaid continues to mentor a number of MSPS and Ph.D. students.  Dr. Elsaid has authored more than 40 research articles in high-impact journals.     

Research interests

As a clinician-scientist, Dr. Elsaid has active research programs in translational pharmacology and practice-based research. 

Dr. Elsaid’s research in translational pharmacology focuses on developing interventions that address unmet clinical need in the area of musculoskeletal diseases, specifically PTOA and Gout.  As such, Dr. Elsaid’s lab is focused on elucidating the mechanisms that contribute to OA development and acute gout exacerbations, evaluating the suitability of various pharmacologic agents with diverse mechanisms of actions as disease modifying agents and investigating biomarkers indicative of OA disease onset and progression.  Additionally, Dr. Elsaid works on developing novel approaches to enhance joint residence of intra-articularly-administered biologics.  Below are some recent publications in this area of research:

Alquraini A, Garguilo S, D’Souza G, Zhang LX, Schmidt TA, Jay GD, Elsaid KA.  The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluids.  Arthritis Res Ther 2015; Arthritis Res Ther 2015;17:353. 

Al-Sharif A, Jamal M, Zhang LX, Larson K, Schmidt TA, Jay GD, Elsaid KA.  Lubricin/Proteoglycan 4 binding to CD44 receptor: A mechanism of the suppression of proinflammatory cytokine-induced synoviocyte proliferation by lubricin.  Arthritis Rheumatol 2015;67(6):1503-13.

Elsaid KA, Zhang L, Shaman Z, Patel C, Schmidt TA, Jay GD.  The impact of early intra-articular administration of interleukin-1 receptor antagonist on lubricin metabolism and cartilage degeneration in an anterior cruciate ligament transection model.  Osteoarthritis Cartilage 2015;23(1):114-21.

Elsaid KA, Ferreira L, Truong T, Liang A, Machan J, D’Souza GG.  Pharmaceutical nanocarrier association with chondrocytes and cartilage explants: influence of surface modification and extracellular matrix depletion.  Osteoarthritis Cartilage 2013;21:377-84.

 

Dr. Elsaid’s research interests in practice-based research focuses on assessing the role that pharmacists play in enhancing the safety and quality of the medication use process with a particular focus on oncology drugs and on evaluating the impact of pharmacist services in the ambulatory setting on select treatment outcomes.  Below are some recent publications in this area of research:

Migliozzi D, Zullo A, Collins C, Elsaid KA.  Achieving blood pressure control among renal transplant recipients by integrating electronic health technology and clinical pharmacy services.  Am J Health-Syst Pharm. 2015;72:1987-92.

Elsaid KA, Garguio S, Collins CM.  Chemotherapy e-prescribing: opportunities and challenges.  Integrated Pharmacy Research and Practice 21 May 2015;2015(4):39-48.

McKaig D, Collins C, Elsaid KA.  Impact of reengineered electronic error-reporting system on medication event reporting and care process improvement at an urban medical center.  Jt Comm J Qual Patient Saf 2014;40(9):398-407.

Elsaid KA, Truong T, Monckberg M, McCarthy H, Butera J, Collins C.  Impact of electronic chemotherapy order forms on prescribing errors at an urban medical center: results from an interrupted time-series analysis.  Int J Qual Health Care 2013;25:656-63.

 

Recent Creative, Scholarly Work and Publications

Qadri M, Elsayed S, Elsaid KA. Fingolimod Phosphate (FTY720-P) Activates Protein Phosphatase 2A in Human Monocytes and Inhibits Monosodium Urate Crystal-Induced IL-1beta Production. J Pharmacol Exp Ther. 2021; 376:222-230. DOI: 10.1124/jpet.120.000321; [PMID: 33239408].
Zoghbi K, Bousoik E, Parang K, Elsaid KA. Design and biological evaluation of colchicine-CD44-targeted peptide conjugate in an in vitro model of crystal induced inflammation. Molecules 2020; 25, 45. DOI: 10.3390/molecules25010046. [PMID: 31877739] [PMCID: PMC6982808].
Bousoik E, Qadri M, Elsaid KA. CD44 receptor mediates crystal phagocytosis by macrophages and regulates inflammation in a murine peritoneal model of acute gout. Sci. Rep. 2020;10:5748:1-15. DOI: 10.1038/s41598-020-62727-z. [PMID: 32238827] [PMCID: PMC7113258].
Qadri M, Jay GD, Zhang LX, Richendrfer H, Schmidt TA, Elsaid KA. Proteoglycan-4 regulates fibroblast to myofibroblast transition and expression of fibrotic genes in the synovium. Arthritis Res Ther. 2020; 22(1):113:1-16. DOI: https://doi.org/10.1186/s13075-020-02207-x. [PMID: 32404156] [PMCID: PMC7222325].
Richendrfer HA, Levy M, Elsaid KA, Schmidt TA, Zhang L, Cabezas R, Jay, GD. Recombinant Human Proteoglycan-4 Mediates Interleukin-6 Response in Both Human and Mouse Endothelial Cells Induced Into a Sepsis Phenotype. Critical Care Explorations: June 2020 - Volume 2 - Issue 6 - p e0126. DOI: 10.1097/CCE.0000000000000126. [PMID: 32695993] [PMCID: PMC7314356].
Hurtig M, Zaghloul I, Sheardown H, Schmidt TA, Liu L, Zhang L, Elsaid KA, Jay GD. Two compartment pharmacokinetic model describes the intra-articular delivery and retention of rhPRG4 following ACL transection in the Yucatan mini pig. J Orthop. Res. 2019 Feb;37(2):386-396.
Qadri M, Almadani S, Jay GD, Elsaid KA. Role of CD44 in regulating TLR2 activation of human macrophages and downstream expression of proinflammatory cytokines. J Immunol 2018 Jan;200(2):758-767. DOI: 10.4049/jimmunol.1700713. [PMID: 29196459] [PMCID: PMC5760314].
Lefebvre AL, Zullo AR, Dappah-Afriyie R, Collins CM, Elsaid KA. Outcomes of a pharmacist-managed clinic for underserved persons with unmanaged type 2 diabetes mellitus. J Pharm Pract Res. 2018 Feb;48(1):65-71. DOI: 10.1002/jppr.1349.
Qadri M, Jay GD, Ostrom R, Zhang L, Elsaid KA. cAMP attenuates TGF-ß’s profibrotic responses in osteoarthritic synoviocytes: involvement of hyaluronan and PRG4. Am J Physiol Cell Physiol. 2018 Jun 13. DOI: 10.1152/ajpcell.00041.2018. [PMID: 29898378].
Qadri M, Jay GD, Zhang LX, Wong W, Reginato A, Sun C, Schmidt T, Elsaid KA. Recombinant human proteoglycan-4 reduces phagocytosis of urate crystals and downstream nuclear factor kappa b and inflammasome activation and production of cytokines and chemokines in human and murine macrophages. Arthritis Res Ther 2018 Aug 29;20(1):192. DOI: 10.1186/s13075-018-1693-x. [PMID: 30157934].
Elsaid KA, Ubhe A, Shaman Z, D’Souza G. Intra-articular interleukin-1 receptor antagonist (IL-1 ra) microspheres for posttraumatic osteoarthritis: in vitro biological activity and in vivo disease modifying effect. J Exp Orthop 2016;3(1):18.
Larson KM, Zhang LX, Elsaid KA, Schmidt TA, Fleming BC, Badger GJ, Jay GD. Reduction of friction by recombinant human proteoglycan-4 in IL-1a stimulated bovine cartilage explants. J Orthop Res 2017;35(3):580-589.
Alquraini A, Jamal M, Zhang L, Schmidt TA, Jay GD, Elsaid KA. The autocrine role of proteoglycan-4 (PRG4) in modulating osteoarthritic synoviocyte proliferation and expression of matrix degrading enzymes. Arthritis Res Ther 2017;19(1):89.